Skip to content
MARKETS / NASDAQ / MDXG
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP

Mimedx Group, Inc. MDXG

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$418.6M
▲ 20.0% YoY
$48.6M
▲ 14.5% YoY
In brief

What this company does

MIMEDX provides a portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. It sources donated birth tissue, namely the human placental membrane, umbilical cord and the placental disc, through a donor network with hospitals and clinician groups. The donated tissue is shipped to its manufacturing facilities in Marietta, Georgia, where it undergoes testing followed by a proprietary tissue manufacturing workflow the company calls the PURION process. MIMEDX has supplied several million allografts, filling direct orders and consignment orders, through December 31, 2025. As of December 31, 2025, the company had 808 full-time employees. For the years ended December 31, 2025, 2024 and 2023, its top ten customers accounted for 22%, 20% and 20%, respectively, of net sales. MIMEDX has secured payer coverage for over 300 million covered lives.

Written from the business description in MIMEDX GROUP, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 25 February 2026. Every sentence was checked against that document before publication.

Growth
USD 418.6M
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 418.6 · Net income 48.6
200M400M-20M-40M201020122014201620182020202220242025
Compound annual growth
+16.1%
+11.0%
+8.4%
+51.9%
+5.1%
+2.1%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +11.0% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
12 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 15.3% · Net 11.6%
-500%-1000%201020122014201620182020202220242025
ROE
FY2025 · ROE 21.6%
50%100%-100%-200%201020122014201620182020202220242025

Each USD of equity produced 22 cents of profit this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2023 · FCF 24.8
10M20M-8M-16M201020122014201620182020202220242025
Net buybacks $M Dividends $M
FY2025 · Dividends — · Net buybacks 0.0
20M40M2015201620172018202020212022202320242025

Total assetsUSD 342.7M
EquityUSD 256.5M
CashUSD 166.1M
Gross debtUSD 18.0M
Net debtUSD -148.2M
Current ratio4.32×

The company holds more cash than debt.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.40.30.30.30.20.20.30.40.30.20.20.10.10.00.00.0
Operating income $B0.10.10.0−0.0−0.0−0.0−0.0−0.00.00.00.00.0−0.0−0.0−0.0−0.0
EBITDA $B0.10.10.0−0.0−0.0−0.0−0.00.00.10.00.00.0−0.0−0.0−0.0−0.0
Income tax $B0.00.0−0.00.00.0−0.0−0.00.0−0.00.0−0.00.00.00.00.00.0
Net income $B0.00.00.1−0.0−0.0−0.0−0.0−0.00.10.00.00.0−0.0−0.0−0.0−0.0
Free cash flow $B··0.0−0.0−0.0···········
EPS, diluted $0.320.280.37−0.33−0.15−0.77−0.24−0.280.560.000.260.05−0.04−0.09−0.14−0.19
Dividend / sh $················
Payout %················
ROE %21.625.393.4··−287.8−60.9−48.6106.20.947.57.6−8.8−48.0−113.3−187.2
Shares out B0.150.150.150.110.110.110.110.110.110.110.110.110.100.090.070.06

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 2 failures · 1 divergences in 77 reconciliationsAUDITED

Reconciled in 13 of 19 fiscal years. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 17 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente2 failures1 divergent
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsDecember 31
Data on record since2010

Share this section

Download image